GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Capex-to-Operating-Cash-Flow

MESO (Mesoblast) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Mesoblast Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Mesoblast's Capital Expenditure for the three months ended in Jun. 2024 was $-0.09 Mil. Its Cash Flow from Operations for the three months ended in Jun. 2024 was $-10.24 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Mesoblast Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Mesoblast's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Capex-to-Operating-Cash-Flow Chart

Mesoblast Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mesoblast Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mesoblast's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Mesoblast's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mesoblast's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Mesoblast's Capex-to-Operating-Cash-Flow falls into.



Mesoblast Capex-to-Operating-Cash-Flow Calculation

Mesoblast's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Jun. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.331) / -48.458
=N/A

Mesoblast's Capex-to-Operating-Cash-Flow for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.086) / -10.241
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mesoblast  (NAS:MESO) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Mesoblast Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Mesoblast's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesoblast Business Description

Industry
Traded in Other Exchanges
Address
55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Mesoblast Headlines

From GuruFocus

Half Year 2024 Mesoblast Ltd Earnings Call Transcript

By GuruFocus Research 02-29-2024

Q3 2023 Mesoblast Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Q3 2021 Mesoblast Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Q3 2022 Mesoblast Ltd Earnings Presentation Transcript

By GuruFocus Research 02-07-2024

Q1 2023 Mesoblast Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Mesoblast Ltd Annual Shareholders Meeting Transcript

By GuruFocus Research 02-07-2024

Mesoblast Ltd Annual Shareholders Meeting Transcript

By GuruFocus Research 02-07-2024